EORTC presentations at CTOS

EORTC will present four abstracts at the Connective Tissue Oncology Society (CTOS) 21st Annual Meeting, which will take place from 9 to 12 Novembre 2016 in Lisbon, Portugal.

Oral abstract session

Second Safety Analysis of A Phase III Randomized Study of Pre-Operative Radiotherapy (RT) Plus Surgery Versus Surgery Alone for Patients With Retro Peritoneal Sarcoma (RPS) – EORTC 62092-22092- STRASS

Oral Session STS: Retroperitoneal STS; Thu 10.11.2016 – 5:10 PM to 5:55 PM

Authors: Sylvie Bonvalot, Rick L. M. Haas, Saskia Litière, Cecile Le Pechoux, Dirk C Strauss, Carol Jane Swallow, Piotr Rutkowski, Chandrajit P. Raut, Michela Lia, Sandrine Marréaud, Alessandro Gronchi

Poster sessions

Prognosis of Patients Receiving First Line Chemotherapy for Advanced Soft Tissue Sarcomas with Locally Advanced Vs Distant Metastasis Vs Both: An EORTC-STBSG Database Analysis

Poster Session 2: STS 095; Friday 11.11.2016 – 6:15 PM to 7:00 PM

Authors: A.J. Verschoor, S. Litière, S. Marréaud, I. Judson, M. Toulmonde, E. Wardelmann, W. van der Graaf, A. Le Cesne, A. Gronchi, H. Gelderblom

Prospective Validation Of A Molecular Signature Predictive Of Response To Trabectedin In Soft-Tissue Sarcomas Within EORTC 62091 Trial

Poster Session 2: STS 096; Friday 11.11.2016 – 6:15 PM to 7:00 PM

Authors: Italiano A, Touati N, Litière S, Butrynski JE, Penel N, Blay JY, Isambert N, Milhem M, Kerst JM, Reyners AKL, Marréaud S, Collin F, Van der Graaf WT, Gelderblom AJ, Gronchi A

Impact on outcome of concomitant administration of gastric acid suppression (GAS) therapy and pazopanib in soft tissue sarcoma (STS) patients treated within EORTC 62043/62072 trials.

Poster Session 2: STS 113; Friday 11.11.2016 — 6:15 PM to 7:00 PM

Authors: Mir O, Touati N, Lia M, Litière S, Le Cesne A, Sleijfer S, Leahy M, Young R, Mathijssen R, Van Erp NP, Gelderblom AJ, Van der Graaf WT, Gronchi A

Pazopanib In Advanced Vascular Sarcomas: An EORTC Soft Tissue And Bone Sarcoma Group Retrospective Analysis

Poster Session 2: STS 123; Friday 11.11.2016 — 6:15 PM to 7:00 PM

Authors: Kollár A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Boccone P, Steeghs N, Safwat A, Katz D,  Duffaud F, Sleijfer S, van der Graaf WT, Touati N, Litière S, Marréaud S, Gronchi A, Kasper B

Back to news list

Related News

  • Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group

  • Clinical Trials Day 2024: a Q&A on pragmatic clinical trials

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC’s Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023